Interdisciplinarity
By Jonathan Kahn, Biopolitical Times guest contributor
| 01. 24. 2011
In 2009, the director of the National Science Foundation gave a key note
address at an interdisciplinary conference on synthetic biology
sponsored by the National Academies. The director opened with the
following joke:
“A synthetic biologist and a social scientist await death
at the hands of an executioner. The executioner asks the social
scientist if he has a final wish. Yes, he says, I have some new findings
on the societal and ethical dimensions of synthetic biology and I want
to present them to the scientific community before I die. The
executioner then turns to the synthetic biologist and asks if she has a
final wish. Yes, she said, just shoot me before I have to listen to that
lecture.”
It’s a good joke. I have sat through many lectures over the years
that make me sympathize with the synthetic biologist. Lest he offend
anyone in the audience, the director quickly followed the joke with a
disclaimer that certainly no one in the present audience harbored such
sentiments. Nonetheless, the joke is instructive on several levels.
Synthetic
biology is merely...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Diaa Hadid and Shweta Desai, NPR | 01.29.2026
MUMBRA, India — The afternoon sun shines on the woman in a commuter-town café, highlighting her almond-shaped eyes and pale skin, a look often sought after by couples who need an egg to have a baby.
"I have good eggs,"...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...